Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the $20 billion world market in infectious disease drugs. However, it’s also the most crowded of the segments with big pharma and small biotech companies alike speeding toward the market. The second volume of Kalorama’s ongoing market study on anti-infectives tackles this large and dynamic segment with a global report on the clinical, regulatory, business, and even political forces that are shaping the rapidly changing antibiotic market.
Don’t forget to check out Volumes I and III of this exciting series! Purchase two volumes and save 10% or purchase the entire series and save 20%!
Volume I: The World Market for Antifungal Medications
Volume III: The World Market for Antiviral Medications
The World Market for Anti-infectives Series – Volumes I-III